Aims: While digital psycho-oncology interventions are increasing used, few have targeted patients with advanced disease. To address this gap, our group co-designed Finding My Way – Advanced (FMW-A), a 6-module self-guided CBT-based program for women with metastatic breast cancer (MBC). The present study aimed to assess the feasibility of this program.
Methods: A single-site pilot randomised controlled trial (RCT) was conducted. Participants were recruited between 27/2/2020-30/6/2021, via direct clinician approach, professional networks and social media. Participants were eligible if diagnosed with metastatic breast cancer, had a life expectancy of at least 6 months, were aged 18 years or over, had internet and email access, and sufficient English language proficiency. Participants were randomised to either the intervention (FMW-A plus usual-care) or usual-care control (“Hope and Hurdles” kit, provided by Breast Cancer Network Australia to all women following diagnosis of MBC). Feasibility outcomes were: recruitment indices (recruitment rates; uptake rates), and retention (program-adherence: modules completed; and attrition: the percentage of participants who did not complete post-treatment survey). Psychosocial outcomes were collected as potential indicators of efficacy.
Results: The recruitment rate over time was delayed because of COVID19 pandemic, amounting to 2.3 per month and the target was not reached (n=35 recruited; n=40 target). Of those approached, the uptake rate was high (n=35/61; 57.3%), but varied by recruitment method. Adherence was modest (M: 2.3 modules accessed per user), and research attrition was moderate, with 50.0% completing their post-treatment surveys (to date). While social media was effective in improving recruitment, this did not correspondingly improve retention.
Conclusions: These results demonstrate the challenges of conducting a trial with this population who face symptom burden (e.g. fatigue, memory and concentration difficulty) and family stressors, amplified by the COVID-19 pandemic, and provide realistic estimates for future psychosocial clinical trials.